Treatment Outcome of Cetuximab Compared with Cisplatin during Radical Radiotherapy for Locally Advanced Head and Neck Cancer

Law, KS; Wong, R.; Yu, Eden S. H.; Cheng, ACK

doi:10.12809/hkjr1615340

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, heterogeneity might partly result from different administration and doses of cisplatin. Cisplatin was given at 40 mg/m 2 weekly in some studies, [ 25 , 28 , 35 , 41 , 42 ] while 100 mg/m 2 was administered every 3 weeks in others studies. The heterogeneity may be reduced after the standardization of the issues in the future.…”

Section: Discussionmentioning

confidence: 99%

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

2020

View full text Add to dashboard Cite

show abstract

“…To assess the efficacy of ExRT compared with ChRT for locally advanced HNSCC patients, we included 25 trials. 15–20,23–41 In human papillomavirus (HPV)-positive subgroups which compared the efficacy of ExRT with that of ChRT, six trials were included. 16,34,39,40,42,43 The subgroups comparing ExRT with RT included five studies, and the data were retrieved only for analyzing the safety of ExRT in contrast to ChRT/RT for locally advanced HNSCC patients.…”

Section: Resultsmentioning

confidence: 99%

Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data

et al. 2020

View full text Add to dashboard Cite

Background: Cetuximab (CTX) has been approved to be administered concurrently with radiotherapy (RT) to treat locally advanced head and neck squamous cell carcinoma (HNSCC). The aim of this study was to assess the efficacy and safety of concurrent CTX with RT (ExRT). Method: The PubMed, Cochrane Library, EMBASE databases were systematically searched to find relevant articles. The combined hazard ratio (HR), risk ratio (RR) and 95% confidence interval were calculated to assess the efficacy and safety of ExRT in contrast to concurrent platinum-based chemotherapy with RT (ChRT). Results: In total, 32 articles with 4556 patients were included. The pooled HRs indicated that ExRT achieved an unfavorable overall survival (HR: 1.86, p < 0.0001), disease-specific survival (HR: 2.58, p = 0.002), locoregional control (HR: 1.94, p < 0.00001), and progression-free survival (HR: 2.04, p = 0.003) compared with ChRT for locally advanced HNSCC patients. In human papillomavirus-positive patient subgroups, ExRT showed inferior disease-specific survival (HR: 2.55, p = 0.009) and locoregional control (HR: 2.27, p < 0.0001) in contrast to ChRT. Additionally, ExRT increased the occurrence of mucositis (RR: 1.17, p < 0.005), skin toxicity (RR: 6.26, p < 0.00001), and infection (RR: 2.27, p = 0.04) compared with non-CTX groups (ChRT and RT), and was associated with lower incidence of anemia (RR: 0.35, p = 0.009), leukocytopenia (RR: 0.17, p < 0.0001), neutropenia (RR: 0.06, p < 0.0001), nausea/vomiting (RR: 0.23, p < 0.0001), and renal toxicity (RR: 0.14, p = 0.007). Conclusion: ChRT should remain the standard treatment for locally advanced HNSCC patients. ExRT was recognized as an effective alternative treatment for locally advanced HNSCC patients who experienced unbearable toxicities caused by non-CTX treatments.

show abstract

Treatment Outcome of Cetuximab Compared with Cisplatin during Radical Radiotherapy for Locally Advanced Head and Neck Cancer

Cited by 2 publications

References 0 publications

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data

Contact Info

Product

Resources

About